Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) CEO Troy Wilson bought 101,119 shares of Kura Oncology stock in a transaction dated Monday, November 16th. The shares were purchased at an average cost of $7.42 per share, for a total transaction of $750,302.98. Following the completion of the transaction, the chief executive officer owned 635,456 shares of the company’s stock, valued at approximately $4,715,083.52. This represents a 18.92% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Troy Edward Wilson also recently made the following trade(s):
- On Friday, November 13th, Troy Wilson bought 98,881 shares of Kura Oncology stock. The stock was purchased at an average price of $7.63 per share, with a total value of $754,462.03.
- On Monday, August 24th, Troy Wilson bought 100,000 shares of Kura Oncology stock. The stock was purchased at an average price of $12.39 per share, with a total value of $1,239,000.00.
Kura Oncology Stock Down 8.8%
KURA traded down $0.68 during trading hours on Monday, reaching $7.09. 2,621,535 shares of the stock traded hands, compared to its average volume of 2,345,466. The firm’s fifty day simple moving average is $10.05 and its two-hundred day simple moving average is $9.76. The company has a market cap of $651.43 million, a price-to-earnings ratio of -2.15 and a beta of 0.56. Kura Oncology, Inc. has a fifty-two week low of $6.75 and a fifty-two week high of $13.90. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.60 and a quick ratio of 4.71.
Wall Street Analyst Weigh In
KURA has been the topic of a number of analyst reports. JPMorgan Chase & Co. assumed coverage on Kura Oncology in a research report on Thursday, October 1st. They set an “overweight” rating and a $30.00 target price on the stock. Morgan Stanley set a $24.00 price target on Kura Oncology in a report on Monday, August 24th. Barclays set a $24.00 price objective on Kura Oncology in a research note on Wednesday, October 14th. Citizens Jmp restated a “market outperform” rating and set a $24.00 price objective on shares of Kura Oncology in a report on Monday, August 24th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a report on Wednesday, October 14th. Eleven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Kura Oncology presently has an average rating of “Moderate Buy” and an average target price of $25.88.
Read Our Latest Stock Report on Kura Oncology
Institutional Trading of Kura Oncology
Several institutional investors have recently added to or reduced their stakes in the stock. Jump Financial LLC boosted its stake in Kura Oncology by 738.8% during the 3rd quarter. Jump Financial LLC now owns 372,409 shares of the company’s stock valued at $3,989,000 after acquiring an additional 328,009 shares during the last quarter. Bleakley Financial Group LLC acquired a new position in Kura Oncology during the 3rd quarter worth $228,000. Focus Advisor Solutions LLC acquired a new position in Kura Oncology during the 3rd quarter worth $286,000. Royce & Associates LP increased its position in shares of Kura Oncology by 8.0% in the 3rd quarter. Royce & Associates LP now owns 658,811 shares of the company’s stock worth $7,056,000 after purchasing an additional 48,826 shares during the last quarter. Finally, ACT Capital Partners L.P. bought a new stake in shares of Kura Oncology in the 3rd quarter worth about $981,000.
Kura Oncology Company Profile
Kura Oncology is a biopharmaceutical company focused on developing precision medicines for cancer. Its research has centered on therapies that target molecular pathways involved in tumor growth and blood cancers. The company’s best-known program is ziftomenib, an oral menin inhibitor developed for acute myeloid leukemia, including forms associated with NPM1 mutations or KMT2A rearrangements. Kura has also worked on other targeted cancer therapies. Based in San Diego, California, Kura conducts drug development and clinical research in the United States and has worked with international partners to advance its programs.
Featured Articles
- Five stocks we like better than Kura Oncology
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
